| Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis K Thorsen, KD Sørensen, AS Brems-Eskildsen, C Modin, M Gaustadnes, ... Molecular & Cellular Proteomics 7 (7), 1214-1224, 2008 | 452 | 2008 |
| First‐trimester combined screening for trisomy 21 at 7–14 weeks' gestation D Wright, K Spencer, K Kagan K, N Tørring, OB Petersen, A Christou, ... Ultrasound in Obstetrics and Gynecology 36 (4), 404-411, 2010 | 146 | 2010 |
| A reassessment of biochemical marker distributions in trisomy 21‐affected and unaffected twin pregnancies in the first trimester HN Madsen, S Ball, D Wright, N Tørring, OB Petersen, KH Nicolaides, ... Ultrasound in obstetrics & gynecology 37 (1), 38-47, 2011 | 102 | 2011 |
| Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines. N Tørring, PE Jørgensen, BS Sørensen, E Nexø Anticancer research 20 (1A), 91-95, 2000 | 102 | 2000 |
| Effects of finasteride on vascular endothelial growth factor S Häggström, N T ‘rring, K M ‘ller, E Jensen, L Lund, JE Nielsen, A Bergh, ... Scandinavian journal of urology and nephrology 36 (3), 182-187, 2002 | 97 | 2002 |
| Plasma levels of trefoil factors are increased in patients with advanced prostate cancer EM Vestergaard, M Borre, SS Poulsen, E Nexø, N Tørring Clinical cancer research 12 (3), 807-812, 2006 | 96 | 2006 |
| SMARCC1 expression is upregulated in prostate cancer and positively correlated with tumour recurrence and dedifferentiation S Heebøll, M Borre, PD Ottosen, CL Andersen, F Mansilla, L Dyrskjøt, ... Histology and histopathology, 2008 | 87 | 2008 |
| Systemic administration of insulin-like growth factor I (IGF-I) causes growth of the rat prostate N Torring, L Vinter-Jensen, SB Pedersen, FB Sorensen, A Flyvbjerg, ... The Journal of urology 158 (1), 222-227, 1997 | 86 | 1997 |
| Are microRNAs located in genomic regions associated with cancer? P Lamy, CL Andersen, L Dyrskjøt, N Tørring, T Ørntoft, C Wiuf British journal of cancer 95 (10), 1415-1418, 2006 | 77 | 2006 |
| Promoter hypomethylation and upregulation of trefoil factors in prostate cancer EM Vestergaard, E Nexø, N Tørring, M Borre, TF Ørntoft, KD Sørensen International journal of cancer 127 (8), 1857-1865, 2010 | 76 | 2010 |
| Genome-wide analysis of allelic imbalance in prostate cancer using the Affymetrix 50K SNP mapping array N Tørring, M Borre, KD Sørensen, CL Andersen, C Wiuf, TF Ørntoft British journal of cancer 96 (3), 499-506, 2007 | 72 | 2007 |
| Comparison of two different methods for measuring anti-mullerian hormone in a clinical series J Hyldgaard, P Bor, HJ Ingerslev, N Tørring Reproductive biology and endocrinology 13, 1-4, 2015 | 67 | 2015 |
| ErbB1 and prostate cancer: ErbB1 activity is essential for androgen‐induced proliferation and protection from the apoptotic effects of LY294002 N Tørring, F Dagnæs‐Hansen, BS Sørensen, E Nexø, NE Hynes The Prostate 56 (2), 142-149, 2003 | 54 | 2003 |
| Snail1 is over‐expressed in prostate cancer S Heebøll, M Borre, PD Ottosen, L Dyrskjøt, TF Ørntoft, N Tørring Apmis 117 (3), 196-204, 2009 | 49 | 2009 |
| Improved performance of first‐trimester combined screening for trisomy 21 with the double test taken before a gestational age of 10 weeks I Kirkegaard, OB Petersen, N Uldbjerg, N Tørring Prenatal Diagnosis: Published in Affiliation With the International Society …, 2008 | 48 | 2008 |
| PAPP‐A, free β‐hCG, and early fetal growth identify two pathways leading to preterm delivery I Kirkegaard, N Uldbjerg, OB Petersen, N Tørring, TB Henriksen Prenatal diagnosis 30 (10), 956-963, 2010 | 44 | 2010 |
| A Hidden Markov Model to estimate population mixture and allelic copy-numbers in cancers using Affymetrix SNP arrays P Lamy, CL Andersen, L Dyrskjot, N Torring, C Wiuf BMC bioinformatics 8, 1-14, 2007 | 36 | 2007 |
| PAPP‐A and free β‐hCG measured prior to 10 weeks is associated with preterm delivery and small‐for‐gestational‐age infants I Kirkegaard, TB Henriksen, N Tørring, N Uldbjerg Prenatal diagnosis 31 (2), 171-175, 2011 | 35 | 2011 |
| Genetic and Epigenetic SLC18A2 Silencing in Prostate Cancer Is an Independent Adverse Predictor of Biochemical Recurrence after Radical Prostatectomy KD SÖrensen, PJ Wild, A Mortezavi, K Adolf, N Tørring, S Heebøll, ... Clinical Cancer Research 15 (4), 1400-1410, 2009 | 34 | 2009 |
| Secretagogin is a new neuroendocrine marker in the human prostate K Adolf, L Wagner, A Bergh, P Stattin, P Ottosen, M Borre, ... The Prostate 67 (5), 472-484, 2007 | 34 | 2007 |
